guest ::
| Home > Publications database > Ultra high-risk PFA ependymoma is characterized by loss of chromosome 6q. > print |
| Home > Publications database > Ultra high-risk PFA ependymoma is characterized by loss of chromosome 6q. > print |
| 001 | 167455 | ||
| 005 | 20240229133541.0 | ||
| 024 | 7 | _ | |a 10.1093/neuonc/noab034 |2 doi |
| 024 | 7 | _ | |a pmid:33580238 |2 pmid |
| 024 | 7 | _ | |a 1522-8517 |2 ISSN |
| 024 | 7 | _ | |a 1523-5866 |2 ISSN |
| 024 | 7 | _ | |a altmetric:100148753 |2 altmetric |
| 037 | _ | _ | |a DKFZ-2021-00359 |
| 041 | _ | _ | |a eng |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Baroni, Lorena |b 0 |
| 245 | _ | _ | |a Ultra high-risk PFA ependymoma is characterized by loss of chromosome 6q. |
| 260 | _ | _ | |a Oxford |c 2021 |b Oxford Univ. Press |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1628160560_25573 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 500 | _ | _ | |a 2021 Aug 2;23(8):1360-1370 |
| 520 | _ | _ | |a Within PF-EPN-A, 1q gain is a marker of poor prognosis, however, it is unclear if within PF-EPN-A additional cytogenetic events exist which can refine risk stratification.Five independent non-overlapping cohorts of PF-EPN-A were analyzed applying genome wide methylation arrays for chromosomal and clinical variables predictive of survival.Across all cohorts, 663 PF-EPN-A were identified. The most common broad copy number event was 1q gain (18.9%), followed by 6q loss (8.6%), 9p gain (6.5%), and 22q loss (6.8%). Within 1q gain tumors, there was significant enrichment for 6q loss (17.7%), 10q loss (16.9%) and 16q loss (15.3%). The 5-year progression free survival (PFS) was strikingly worse in those patients with 6q loss, with a 5-year PFS of 50% (95%CI 45-55%) for balanced tumors, compared with 32% (95%CI 24-44%) for 1q gain only, 7.3% (95%CI 2.0-27%) for 6q loss only and 0 for both 1q gain and 6q loss (p=1.65x10 -13 ). After accounting for treatment, 6q loss remained the most significant independent predictor of survival in PF-EPN-A but is not in PF-EPN-B. Distant relapses were more common in 1q gain irrespective of 6q loss. RNA-sequencing comparing 6q loss to 6q balanced PF-EPN-A suggests that 6q loss forms a biologically distinct group.We have identified an ultra high-risk PF-EPN-A ependymoma subgroup, which can be reliably ascertained using cytogenetic markers in routine clinical use. A change in treatment paradigm is urgently needed for this particular subset of PF-EPN-A where novel therapies should be prioritized for upfront therapy. |
| 536 | _ | _ | |a 312 - Funktionelle und strukturelle Genomforschung (POF4-312) |0 G:(DE-HGF)POF4-312 |c POF4-312 |f POF IV |x 0 |
| 588 | _ | _ | |a Dataset connected to CrossRef, PubMed, |
| 650 | _ | 7 | |a 1q gain |2 Other |
| 650 | _ | 7 | |a 6qloss |2 Other |
| 650 | _ | 7 | |a PFA |2 Other |
| 650 | _ | 7 | |a PFB |2 Other |
| 650 | _ | 7 | |a ependymoma |2 Other |
| 650 | _ | 7 | |a posterior fossa |2 Other |
| 650 | _ | 7 | |a subgrouping |2 Other |
| 700 | 1 | _ | |a Sundaresan, Lakshmikirupa |b 1 |
| 700 | 1 | _ | |a Heled, Ayala |b 2 |
| 700 | 1 | _ | |a Coltin, Hallie |b 3 |
| 700 | 1 | _ | |a Pajtler, Kristian W |0 P:(DE-He78)a7c1bbac024fa232d9c6b78443328d9d |b 4 |u dkfz |
| 700 | 1 | _ | |a Lin, Tong |b 5 |
| 700 | 1 | _ | |a Merchant, Thomas E |b 6 |
| 700 | 1 | _ | |a McLendon, Roger |b 7 |
| 700 | 1 | _ | |a Faria, Claudia |b 8 |
| 700 | 1 | _ | |a Buntine, Molly |b 9 |
| 700 | 1 | _ | |a White, Christine L |b 10 |
| 700 | 1 | _ | |a Pfister, Stefan M |0 P:(DE-He78)f746aa965c4e1af518b016de3aaff5d9 |b 11 |u dkfz |
| 700 | 1 | _ | |a Gilbert, Mark R |b 12 |
| 700 | 1 | _ | |a Armstrong, Terri S |b 13 |
| 700 | 1 | _ | |a Bouffet, Eric |b 14 |
| 700 | 1 | _ | |a Kumar, Sachin |b 15 |
| 700 | 1 | _ | |a Taylor, Michael D |b 16 |
| 700 | 1 | _ | |a Aldape, Kenneth D |b 17 |
| 700 | 1 | _ | |a Ellison, David W |b 18 |
| 700 | 1 | _ | |a Gottardo, Nicholas G |b 19 |
| 700 | 1 | _ | |a Kool, Marcel |0 P:(DE-He78)4c28e2aade5f44d8eca9dd8e97638ec8 |b 20 |u dkfz |
| 700 | 1 | _ | |a Korshunov, Andrey |0 P:(DE-He78)8d9c904a6cea14d4c99c78ba46e41f93 |b 21 |u dkfz |
| 700 | 1 | _ | |a Hansford, Jordan R |b 22 |
| 700 | 1 | _ | |a Ramaswamy, Vijay |b 23 |
| 773 | _ | _ | |a 10.1093/neuonc/noab034 |g p. noab034 |0 PERI:(DE-600)2094060-9 |n 8 |p 1360-1370 |t Neuro-Oncology |v 23 |y 2021 |x 1523-5866 |
| 909 | C | O | |o oai:inrepo02.dkfz.de:167455 |p VDB |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 4 |6 P:(DE-He78)a7c1bbac024fa232d9c6b78443328d9d |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 11 |6 P:(DE-He78)f746aa965c4e1af518b016de3aaff5d9 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 20 |6 P:(DE-He78)4c28e2aade5f44d8eca9dd8e97638ec8 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 21 |6 P:(DE-He78)8d9c904a6cea14d4c99c78ba46e41f93 |
| 913 | 1 | _ | |a DE-HGF |b Gesundheit |l Krebsforschung |1 G:(DE-HGF)POF4-310 |0 G:(DE-HGF)POF4-312 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-300 |4 G:(DE-HGF)POF |v Funktionelle und strukturelle Genomforschung |x 0 |
| 913 | 0 | _ | |a DE-HGF |b Gesundheit |l Krebsforschung |1 G:(DE-HGF)POF3-310 |0 G:(DE-HGF)POF3-312 |3 G:(DE-HGF)POF3 |2 G:(DE-HGF)POF3-300 |4 G:(DE-HGF)POF |v Functional and structural genomics |x 0 |
| 914 | 1 | _ | |y 2021 |
| 915 | _ | _ | |a Nationallizenz |0 StatID:(DE-HGF)0420 |2 StatID |d 2020-08-32 |w ger |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |d 2020-08-32 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |d 2020-08-32 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0320 |2 StatID |b PubMed Central |d 2020-08-32 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |d 2020-08-32 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0160 |2 StatID |b Essential Science Indicators |d 2020-08-32 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1110 |2 StatID |b Current Contents - Clinical Medicine |d 2020-08-32 |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0113 |2 StatID |b Science Citation Index Expanded |d 2020-08-32 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |d 2020-08-32 |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b NEURO-ONCOLOGY : 2018 |d 2020-08-32 |
| 915 | _ | _ | |a IF >= 10 |0 StatID:(DE-HGF)9910 |2 StatID |b NEURO-ONCOLOGY : 2018 |d 2020-08-32 |
| 920 | 1 | _ | |0 I:(DE-He78)B062-20160331 |k B062 |l B062 Pädiatrische Neuroonkologie |x 0 |
| 920 | 1 | _ | |0 I:(DE-He78)HD01-20160331 |k HD01 |l DKTK HD zentral |x 1 |
| 920 | 1 | _ | |0 I:(DE-He78)B300-20160331 |k B300 |l KKE Neuropathologie |x 2 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a I:(DE-He78)B062-20160331 |
| 980 | _ | _ | |a I:(DE-He78)HD01-20160331 |
| 980 | _ | _ | |a I:(DE-He78)B300-20160331 |
| 980 | _ | _ | |a UNRESTRICTED |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|